CIK 0001434316
- Non-accelerated filer
- Smaller reporting company
FATE THERAPEUTICS INC
Sign in to watch- Ticker
- FATE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 651311552
- Phone
- +1 858-875-1803
- Business address
- 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $13,525
- in 1 filing
Net −$13,525. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise | +10,000 | $2.73 | $27K | 403,793 |
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise | +4,846 | $4.84 | $23K | 408,639 |
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise | +15,154 | $2.70 | $41K | 423,793 |
| 2021-10-22 | Wolchko J Scott President and CEO | Sale | −30,000 | $58.88 | $1.8M | 393,793 |
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −10,000 | 50,000 | ||
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −4,846 | 0 | ||
| 2021-10-22 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −15,154 | 99,446 | ||
| 2021-10-21 | Wolchko J Scott President and CEO | Option exercise | +30,000 | $2.73 | $82K | 423,793 |
| 2021-10-21 | Wolchko J Scott President and CEO | Sale | −15,235 | $59.82 | $911K | 408,558 |
| 2021-10-21 | Wolchko J Scott President and CEO | Sale | −14,765 | $60.63 | $895K | 393,793 |
| 2021-10-21 | Wolchko J Scott President and CEO | Option exercise · Stock Option (Right to Buy) | −30,000 | 60,000 | ||
| 2021-10-01 | TAHL CINDY General Counsel and Secretary | Option exercise | +50,000 | $6.55 | $328K | 158,048 |
| 2021-10-01 | TAHL CINDY General Counsel and Secretary | Sale | −16,312 | $58.03 | $947K | 141,736 |
| 2021-10-01 | TAHL CINDY General Counsel and Secretary | Sale | −21,844 | $58.96 | $1.3M | 119,892 |
| 2021-10-01 | TAHL CINDY General Counsel and Secretary | Sale | −11,844 | $59.68 | $707K | 108,048 |
| 2021-10-01 | TAHL CINDY General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −50,000 | 116,643 | ||
| 2021-09-28 | Dulac Edward J III Chief Financial Officer | Option exercise | +17,325 | $35.52 | $615K | 71,864 |
| 2021-09-28 | Dulac Edward J III Chief Financial Officer | Sale | −19,460 | $62.53 | $1.2M | 52,404 |
| 2021-09-28 | Dulac Edward J III Chief Financial Officer | Option exercise · Stock Option (Right to Buy) | −17,325 | 142,675 | ||
| 2021-09-13 | Valamehr Bahram Chief Development Officer | Option exercise | +25,000 | $2.73 | $68K | 120,740 |
Page 16 of 26 · 503 trades